The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | An investigator-initiated trial of zamto-cel, a dual-targeted CAR-T therapy, in R/R MCL
Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, comments on an investigator-initiated trial of zamtocabtagene autoleucel (zamto-cel), a dual-targeted CAR-T therapy, in relapsed/refractory (R/R) mantle cell lymphoma (MCL). Dr Shah reports a high overall response rate and favorable safety profile, paving the way for a Phase II trial. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So our group has done some work as an IIT, so investigator-initiated trial, and so we use the exact same construct as zamto-cel. So it’s the same CAR-T, but we recently published a paper looking at this CAR as a single-center clinical trial in mantle cell lymphoma. And so those of you who treat mantle cell know that in the relapsed/refractory state, it can be a difficult disease to treat...
So our group has done some work as an IIT, so investigator-initiated trial, and so we use the exact same construct as zamto-cel. So it’s the same CAR-T, but we recently published a paper looking at this CAR as a single-center clinical trial in mantle cell lymphoma. And so those of you who treat mantle cell know that in the relapsed/refractory state, it can be a difficult disease to treat. But one of the hallmarks of mantle cell is that it is CD20 bright. And so a dual-targeted CAR targeting 20 and 19, we hypothesize could be efficacious. And as part of this clinical trial, we treated 17 patients with relapse-refractory mantle and actually report an overall response rate of 100%. And so that was really, really exciting for us. Of that cohort, only two patients relapsed with the disease. And we actually have a median follow-up of almost 20 months. And so that data was published recently in the Journal of Clinical Oncology where you can see the full data set. And then in terms of safety, again, no grade three or higher cytokine release syndrome and low rates, manageable, of grade three and higher neurotoxicity. So actually, zamto-cel is now being developed as part of a multi-center phase two study as part of the same clinical trial that the DLBCL is running in. And we’re enrolling patients throughout the United States right now.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
